Adequate vitamin D is associated with favorable disease outcome in children with inflammatory bowel disease receiving anti‐tumor necrosis factor alpha therapy
Journal of Pediatric Gastroenterology and Nutrition · 2026
DOI: 10.1002/jpn3.70321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Adi Anafy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, affiliated to the Gray Faculty of Medical an…. Hauptthemen laut MEDLINE: Vitamin D, Tumor Necrosis Factor-alpha, Vitamin D Deficiency, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Deficiency of serum 25‐hydroxyvitamin D [25(OH)D] was associated with decreased short‐term response to anti‐tumor necrosis factor‐alpha (TNF‐α) agents in adults with inflammatory bowel disease (IBD). The aim of this study was to evaluate the association between serum 25(OH)D levels and the outcome of children with IBD undergoing anti‐TNF‐α therapy.
Methods
Children with IBD who were treated with anti‐TNF‐α agents and whose 25(OH)D levels had been measured at the initiation of therapy were included. Demographic, clinical, and laboratory data were collected retrospectively between 1/2012 and 1/2022. 25(OH)D levels above 30 ng/mL were considered sufficient.
Results
A total of 150 children with IBD were treated with anti‐TNF‐α agents, and 84 of them (58 Crohn's disease, 26 ulcerative colitis, median [interquartile range] age 15.2 [12.8–16.5] years) met the inclusion criteria. Sixty‐five (77%) patients were 25(OH)D‐deficient. Adequate 25(OH)D levels were associated with clinical response (hazard ratio [HR] = 4, 95% confidence interval [CI] 1.43–11.11, p = 0.008), and clinical remission (HR = 4.62, 95% CI 2.56–8.33, p < 0.001). While anti‐TNF‐α trough levels were comparable between 25(OH) d ‐deficient and non‐deficient children, intensification of anti‐TNF‐α therapy was more prevalent among children with 25(OH)D deficiency (65% vs. 21%, p < 0.001).
Conclusions
Adequate serum 25(OH)D is an independent predictor of a favorable outcome of pediatric IBD under anti‐TNF‐α therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, affiliated to the Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Pediatrics, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, affiliated to the Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Pediatrics, Assuta Ashdod University Medical Center, Ashdod, Israel, and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
ORCID-Profile: Adi Anafy
Förderung
- None
Zitieren
APA
Anafy, A., Manor, Y., Shemer, M., Doyev, R., Damari, E., Cohen, S., & Yerushalmy-Feler, A. (2026). Adequate vitamin D is associated with favorable disease outcome in children with inflammatory bowel disease receiving anti‐tumor necrosis factor alpha therapy. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70321
Vancouver
Anafy A, Manor Y, Shemer M, Doyev R, Damari E, Cohen S, et al. Adequate vitamin D is associated with favorable disease outcome in children with inflammatory bowel disease receiving anti‐tumor necrosis factor alpha therapy. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70321
BibTeX
@article{Anafy2026,
author = {Anafy, Adi and Manor, Yaara and Shemer, Maayan and Doyev, Reut and Damari, Eytan and Cohen, Shlomi and Yerushalmy-Feler, Anat},
title = {Adequate vitamin D is associated with favorable disease outcome in children with inflammatory bowel disease receiving anti‐tumor necrosis factor alpha therapy},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70321}
}
EUVIMED